Faulk K, Kairalla J, Devidas M, Hibbitts E, Carroll A, Heerema N, Kubaney H, August A, Pauly M, Wechsler D, Miles R, Reid J, Druley T, Kihei C, Gore L, Raetz E, Hunger S, Loh M, Brown P, Guest E. Pegaspargase levels in infants with ALL: A report from the Children’s Oncology Group trial AALL15P1. International Society of Paediatric Oncology (SIOP), Barcelona, Spain, September 2022. Poster Presentation.
Faulk K, Kairalla J, Devidas M, Hibbitts E, Carroll A, Heerema N, Kubaney H, August A, Pauly M, Wechsler D, Miles R, Reid J, Druley T, Kihei C, Gore L, Raetz E, Hunger S, Loh M, Brown P, Guest E. Pegaspargase levels in infants with ALL: A report from the Children’s Oncology Group trial AALL15P1. The American Society of Pediatric Hematology/Oncology (ASPHO), Pittsburgh, PA, May 2022. Poster Presentation.
Lamble A, Yeuh-Yun C, Verma A, Faulk K, Stevens A, Pommert L, Tucker S, Brookhart B, Shah NN, Brooks C, Mughal T, Cooper T. Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial. American Society of Hematology (ASH), New Orleans, LA, December 2022. Poster Presentation.
Faulk KE, Anderson-Mellies A, Cockburn M, Green AL. Assessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015. PLoS One. 2020; 15(4)e0230824.
The Safety of SARS-Cov-2 Vaccines in Persons with a Known History of Pegaspargase Allergy: A Single Institution Experience. The Journal of Allergy and Clinical Immunology: In Practice, accepted with revisions.
Cheung L, Aya-Bonilla C, Cruickshank M, Chiu S, Keuk V, Anderson D, Chua G-A, Singh S, Oommen J, Ferrari Em Hughes A, Ford J, Kunold E, Hesselman M, Post F, Faulk KE, Breese E, Guest E, Brown P, Loh M, Lock R, Kees U, Jafari R, Malinge S, Kotecha R. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged ALL reveals a new therapeutic strategy. Leukemia. In-press, 2022.
Clinical Interests
My clinical interest is in early phase clinical trials and translational research in novel pediatric cancer treatments, with a particular emphasis on high risk pediatric cancers and hematologic malignancies.
General Information
Medical Schools:
MD, University of Colorado Denver School of Medicine
(2012)
Graduate Schools:
MSCS, University of Colorado Health Sciences Center
(2019)
Undergraduate Schools:
BA, University of Colorado - Boulder (CO)
(2007)
Internships:
University of Colorado (Children's Hospital Colorado) Program
(2012)
Residency Programs:
University of Colorado (Children's Hospital Colorado) Program, Pediatrics (2015)
Fellowships:
University of Colorado (Children's Hospital Colorado) Program, Pediatric Hematology / Oncology
(2018)
University of Colorado (Children's Hospital Colorado) Program, Experimental Therapeutics
(2019)